JP2021523379A - 血清バイオマーカー - Google Patents

血清バイオマーカー Download PDF

Info

Publication number
JP2021523379A
JP2021523379A JP2020564247A JP2020564247A JP2021523379A JP 2021523379 A JP2021523379 A JP 2021523379A JP 2020564247 A JP2020564247 A JP 2020564247A JP 2020564247 A JP2020564247 A JP 2020564247A JP 2021523379 A JP2021523379 A JP 2021523379A
Authority
JP
Japan
Prior art keywords
subject
treatment
biomarkers
expression
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523379A5 (https=
JPWO2019219612A5 (https=
Inventor
ホルト，ロバート
ミクレム，デイビッド
Original Assignee
ベルゲンビオ アーエスアー
ベルゲンビオ アーエスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807789.1A external-priority patent/GB201807789D0/en
Priority claimed from GBGB1816764.3A external-priority patent/GB201816764D0/en
Priority claimed from GBGB1817024.1A external-priority patent/GB201817024D0/en
Application filed by ベルゲンビオ アーエスアー, ベルゲンビオ アーエスアー filed Critical ベルゲンビオ アーエスアー
Publication of JP2021523379A publication Critical patent/JP2021523379A/ja
Publication of JP2021523379A5 publication Critical patent/JP2021523379A5/ja
Publication of JPWO2019219612A5 publication Critical patent/JPWO2019219612A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2020564247A 2018-05-14 2019-05-13 血清バイオマーカー Pending JP2021523379A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1807789.1 2018-05-14
GBGB1807789.1A GB201807789D0 (en) 2018-05-14 2018-05-14 Serum biomarkers
GBGB1816764.3A GB201816764D0 (en) 2018-10-15 2018-10-15 Serum biomarkers
GB1816764.3 2018-10-15
GBGB1817024.1A GB201817024D0 (en) 2018-10-19 2018-10-19 Serum biomarkers
GB1817024.1 2018-10-19
PCT/EP2019/062215 WO2019219612A1 (en) 2018-05-14 2019-05-13 Serum biomarkers

Publications (3)

Publication Number Publication Date
JP2021523379A true JP2021523379A (ja) 2021-09-02
JP2021523379A5 JP2021523379A5 (https=) 2022-05-20
JPWO2019219612A5 JPWO2019219612A5 (https=) 2022-05-20

Family

ID=66589527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564247A Pending JP2021523379A (ja) 2018-05-14 2019-05-13 血清バイオマーカー

Country Status (5)

Country Link
US (1) US20210215697A1 (https=)
EP (1) EP3794352A1 (https=)
JP (1) JP2021523379A (https=)
CN (1) CN112639474A (https=)
WO (1) WO2019219612A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004189D0 (en) * 2020-03-23 2020-05-06 Bergenbio As Combination therapy
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
WO2023059527A1 (en) * 2021-10-04 2023-04-13 Tintoria Piana, Inc. Diagnostic system and methods of using and manufacturing the same
CN118359697A (zh) * 2024-04-29 2024-07-19 上海硅羿生物技术有限公司 β淀粉样蛋白40及β淀粉样蛋白42特异识别多肽及其应用
CN121186348B (zh) * 2025-11-25 2026-02-24 北京大学人民医院 瓜氨酸化内凝集素-1多肽在制备类风湿关节炎诊断产品中的应用
CN121186360B (zh) * 2025-11-25 2026-04-14 长兴固容生物科技有限公司 一种用于乳腺癌筛查、诊断的标志物组及其用途
CN121186365B (zh) * 2025-11-25 2026-04-14 长兴固容生物科技有限公司 一种用于胰腺癌筛查、诊断的标志物组及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539794A (ja) * 2005-05-18 2008-11-20 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
WO2017009261A1 (en) * 2015-07-10 2017-01-19 Bergenbio As Biomarkers for cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO2014055543A2 (en) * 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) * 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
CA2971763A1 (en) 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539794A (ja) * 2005-05-18 2008-11-20 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
WO2017009261A1 (en) * 2015-07-10 2017-01-19 Bergenbio As Biomarkers for cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ADAM CLOE: "FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia: An Evaluation of Efficacy of Target Inh", BLOOD, vol. 126, no. 23, JPN6023016091, 2015, pages 4940, XP086648755, ISSN: 0005045168, DOI: 10.1182/blood.V126.23.4940.4940 *
C ROCHLITZ: "Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo", LEUKEMIA, vol. 13, JPN6023016087, 1999, pages 1352 - 1358, ISSN: 0005195759 *
CHRISTINA WANG: "Effect of Combination Chemotherapy on Pituitary-Gonadal Function in Patients with Lymphoma and Leuke", CANCER, vol. 45, JPN6023016095, 1980, pages 2030 - 2037, ISSN: 0005045172 *
CLAUDIA M GORCEA: "ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: backgroun", FUTURE ONCOL, vol. 14, no. 20, JPN6023016094, 2 March 2018 (2018-03-02), pages 1995 - 2004, ISSN: 0005045171 *
IL-KYOO PARK: "The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloi", BLOOD, vol. 124, no. 21, JPN6023016085, 6 December 2014 (2014-12-06), pages 2350, XP086741155, ISSN: 0005045162, DOI: 10.1182/blood.V124.21.2350.2350 *
IL-KYOO PARK: "The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloi", BLOOD, vol. 124, no. 21, JPN6023016090, 2014, pages 2350, XP086741155, ISSN: 0005045167, DOI: 10.1182/blood.V124.21.2350.2350 *
ISABEL BEN-BATALLA: "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of l", BLOOD, vol. 122, no. 14, JPN6023016086, 2013, pages 2443 - 2452, XP055242664, ISSN: 0005195758, DOI: 10.1182/blood-2013-03-491431 *
KENSUKE USUKI: "Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemi", CANCER SCIENCE, vol. 109, JPN6023016093, 2018, pages 3235 - 3244, ISSN: 0005045170 *
LOGES S: "The immunomodulatory activity of bemcentinib (BGB324) - a first-in-class selective, oral AXL inhibit", ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM, JPN6023016089, 25 January 2018 (2018-01-25), ISSN: 0005045166 *
PETER RUVOLO: "AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth", BLOOD, vol. 128, no. 22, JPN6023016092, 2016, pages 3939, ISSN: 0005045169 *
SONJA LOGES: "The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire", BLOOD, vol. 130, no. 1, JPN6023016088, 7 December 2017 (2017-12-07), pages 1375, XP086630249, ISSN: 0005195760, DOI: 10.1182/blood.V130.Suppl_1.1375.1375 *
TSUYOSHI MUTA: "Anti-haptoglobin antibody detection after febrile non-hemolytic transfusion reactions in a non-hapto", TRANSFUSION AND APHERESIS SCIENCE, vol. 41, JPN6023016096, 2009, pages 171 - 173, XP026761304, ISSN: 0005045173, DOI: 10.1016/j.transci.2009.09.003 *

Also Published As

Publication number Publication date
US20210215697A1 (en) 2021-07-15
CN112639474A (zh) 2021-04-09
WO2019219612A1 (en) 2019-11-21
EP3794352A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
JP2021523379A (ja) 血清バイオマーカー
US10613091B2 (en) Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
US20240103003A1 (en) Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
DK2240781T3 (en) METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
US10247730B2 (en) Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient
JP5224308B2 (ja) 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
JP2015533084A (ja) 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
EP2933639A1 (en) S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN107250796B (zh) 用于鉴别对雄激素受体靶向疗法的抵抗性的循环肿瘤细胞诊断
CN103384832B (zh) 用于在猫科动物中诊断和治疗肾功能障碍的组合物和方法
US20190331683A1 (en) Biomarkers of Rapid Progression in Advanced Non-Small Cell Lung Cancer
JP2021531751A (ja) アデノシン経路活性化を有する癌を検出および治療するための方法
EP2718720B1 (en) Prediction of recurrence for bladder cancer by a protein signature in tissue samples
Ren et al. Tumor markers for early detection of ovarian cancer
Khosravi et al. Calprotectin as new potential clinical marker for multiple myeloma
WO2017201166A1 (en) Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
EP2307561A2 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
HK40046705A (en) Serum biomarkers
EP4189397A2 (en) Methods for the determination of the predisposition for a severe or critical course of a covid-19-disease from a mild or moderate course of a covid-19-disease in a subject
KR102737876B1 (ko) 유방암 환자의 선행 항암화학요법 후 예후 예측을 위한 바이오마커 및 이의 용도
Zeng et al. CRISPR/Cas12a Integrated with a Microfluidic System Enhanced Analysis of Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells from Non-Small Cell Lung Cancer Patients
US20210263038A1 (en) Composition for diagnosis of bone metastasis of cancer and kit comprising same
CN119546782A (zh) 高风险鼻咽癌的检测方法
KR20210100833A (ko) 혈액 종양 질환 특이적 바이오마커

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114